CPH.AX - Creso Pharma Limited
ASX - ASX Delayed price. Currency in AUD
At close: 04:10PM AEST
Stock chart is not supported by your current browser
| Previous close | 0.0090 |
| Open | 0.0090 |
| Bid | 0.0090 x 41816300 |
| Ask | 0.0100 x 96874000 |
| Day's range | 0.0090 - 0.0090 |
| 52-week range | 0.0080 - 0.0530 |
| Volume | |
| Avg. volume | 9,576,445 |
| Market cap | 23.106M |
| Beta (5Y monthly) | 2.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 29 Aug 2023 - 04 Sept 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Creso Pharma Insiders Lose Out As Stock Sinks To AU$0.009 \
Insiders who acquired AU$300k worth of Creso Pharma Limited's ( ASX:CPH ) stock at an average price of AU$0.04 in the...
- Simply Wall St.
Creso Pharma Full Year 2022 Earnings: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)
Creso Pharma ( ASX:CPH ) Full Year 2022 Results Key Financial Results Revenue: AU$9.03m (up 45% from FY 2021). Net...
PR NewswireHalucenex Life Sciences Inc. targets Australian market following landmark TGA decision
Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma') is pleased to announce its wholly-owned psychedelics subsidiary, Halucenex Life Sciences Inc. ('Halucenex'), is exploring opportunities to register its synthetic psilocybin formulation for the Australian market following recent regulatory changes.